MedTrace Logo

Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block

NCT03385967 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2019-05-23

No results posted yet for this study

Summary

This is a prospective, randomized, double blind study of adding dexmedetomidine to ropivacaine for Brachial plexus block and assessing the analgesia with VAS pain scales(0-10), Satisfaction scale by VAS scale(0-10) and time to first analgesic consumption. This study mainly aims to investigate whether addition of dexmedetomidine helps in increasing the duration of analgesia.

Conditions

  • Analgesia
  • Pain, Acute
  • Peripheral Nerve Block

Interventions

DRUG

Dexmedetomidine

Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine

DRUG

ropivacaine

Standard of care 0.5%ropivacaine

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Alberto Ardon, MD · University of Florida College of Medicine Jacksonville

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385967 on ClinicalTrials.gov